A Case of Refractory Choriocarcinoma that Showed Complete Remission with Paclitaxel.
- Author:
Yun Hyun CHO
1
;
Mi Kyung KIM
;
Sang In JUNG
;
Jong Yun WHANG
;
Ji Hyung CHO
;
Young Tak KIM
;
Joo Hyun NAM
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Refractory choriocarcinoma;
Chemotherpy;
Paclitaxel
- MeSH:
Adult;
Choriocarcinoma*;
Cyclophosphamide;
Dactinomycin;
Drug Therapy;
Female;
Humans;
Methotrexate;
Paclitaxel*;
Pregnancy;
Prognosis
- From:Korean Journal of Obstetrics and Gynecology
2002;45(6):1097-1100
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
High-risk gestational choriocarcinoma in patients who have failed primary chemotherapy is known to have a very poor prognosis. About 25% of high-risk metastatic choriocarcinoma become refractory to EMACO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) and fail to achieve a complete remission. Currently, there is no standard salvage chemotherapeutic regimen for EMACO refractory choriocarcinoma. Paclitaxel, a taxane analog extracted from the bark of the western yew, has shown antitumor activity in a variety of cancers. However, there has been few case reports that described the effectiveness of paclitaxel to choriocarcinoma. We describe a 41-year old woman with refractory choriocarcinoma, who demonstrated dramatic response to paclitaxel treatment with a brief review of literature.
